Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Jan 19, 2016 6:11pm
242 Views
Post# 24474245

Can we narrow these down to a particular month?

Can we narrow these down to a particular month?In the post from Closly on expected or hoped for catalysts upcoming in Q1 or H1 2016 I wonder if we can guesstimate for those events that I have selected to a particular month rather than to Q1 or even worse to H1?

The events of interest to me are those  that could lead to a push to share price and are not mere speculation or just the start of a trial or process but are rather the end or readout  of a trial or process.

They are:

2.     Q1 preliminary review of the Cdn IPF data.
3.     Q1 Preliminary review of the UK MS/fibrosis data. 
....
15.  H1 Data from the MS/fibrosis trials in the UK
16.  H1 PBI-4050 Results of preliminary data review of Canadian IPF trial (April/May)
.....
20.   H2 BLA filing with FDA for Plasminogen approval

Any others that we missed?

.....
glta
Stockman6767
---------------------------------------------------------------

RE:Prometic 2016 New Year’s list

Closly wrote: .    1.     First month Partnership deal on PBI-4050 (London or Japan) Both?
2.     Q1 preliminary review of the Cdn IPF data.
3.     Q1 Preliminary review of the UK MS/fibrosis data.
4.     Q1 Announcing another orphan indication
5.     Q1 Contract API supply
6.     Q1 Resin sale contract
7.     H1 Initiate an open label, placebo-controlled pivotal phase II study for T2 diabetes patients in Canada
8.     H1 Plasminogen Initiation of the Phase II/III trial in Plasminogen deficiency
9.     H1 Submission of the IND application
10.  H1 C1-INH Submission of the IND application start clinical trials
11.  H1 PBI-4050 Submission of IND for IPF Pivotal Trial Phase II/III study in the United States
12.  H1 PBI-4050 Submission of IND for Metabolic Syndrome Pivotal Trial
13.  H1 PBI-4050 Submission and approval of IND for CKD Phase II trial
14.  H1 File IND for AAT – start clinical trials
15.  H1 Data from the MS/fibrosis trials in the UK
16.  H1 PBI-4050 Results of preliminary data review of Canadian IPF trial (April/May)
17.  H2 File IND for plasminogen, wound care indication – start clinical trials
18.  H2 Start pivotal Phase III study for IVIG
19.  H2 contract on Plasminogen for wound healing
20.   H2 BLA filing with FDA for Plasminogen approval
21. H2 new facilities in USA
 

Bullboard Posts